NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Prescribing
  • Key to symbols

3 Respiratory system

3.7 Mucolytics

Preferred list
CARBOCISTEINE

Prescribing Notes:

Discontinue use after 4 weeks if the patient fails to derive any benefit (see BNF).  The dose of carbocisteine should be reduced to a maintenance dose of 1.5g daily in divided doses as the patient's condition improves. Typically, such a dose reduction would be done after one month of treatment

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/3062.htm

Total Formulary
DORNASE ALFA

Restrictions: Restricted to specialist initiation.

Prescribing Notes:

Responsibility for initiation, review and any necessary monitoring rests with specialist service.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/20296.htm

MANNITOL (BRONCHITOL) (powder for inhalation)

Restrictions: Restricted to specialist initiation for use in cystic fibrosis patients who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and have rapidly declining lung function and in whom other osmotic agents are considered unsuitable.

BNF Link: http://www.medicinescomplete.com/mc/bnf/current/PHP18713-mannitol.htm